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Purpose: To report clinical characteristics of optic neuritis (ON) in Koreans >50 years of age.
Methods: A retrospective chart review was performed on patients with ON between January 2000 and Decem-
ber 2009. We obtained the best-corrected visual acuity (BCVA), Goldmann perimetry, relative afferent pupillary 
defect (RAPD), and color function tests as well as brain magnetic resonance imaging (MRI) findings in patients 
who were in the acute stage of the disorder. 
Results: Nine eyes in eight patients were included. The mean age of patients at presentation was 60.5 years 
(range, 53 to 71 years). Six patients were female, and two were male. There was one patient with bilateral 
ON. The mean BCVA at presentation was 20 / 400 (no light perception-20 / 70). Eight eyes (89%) complained 
of pain with eye movement. Six eyes (66%) had disc edema. Central scotoma was the most common field 
defect. All eyes had color abnormalities. Five eyes in four patients showed abnormalities of the involved optic 
nerves on MRI. The patients were followed for a mean of 11.3 months (range, 2 to 34 months). All of the pa-
tients recovered to a BCVA of 20 / 40 or better within 2 months. On the last follow-up, the mean BCVA was 20 
/ 20 (20 / 40 to 20 / 16). Four eyes showed remnant central scotoma. One eye had remnant RAPD, and two 
eyes had mild color abnormalities.
Conclusions: Although ON is uncommon in elderly patients, it can develop in patients >50 years of age, and 
clinical features of optic neuritis in elderly patients are similar to those of younger patients.
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Optic neuritis (ON) is an acute inflammatory condition 
affecting the optic nerve. The most common cause of ON 
is demyelination of the optic nerve (either idiopathic or due 
to multiple sclerosis), although there are other possible eti-
ologies, including para-infectious responses, infections and 
vasculitides. ON typically affects young adults between 
18 and 45 years of age, with a mean age of 30 to 35 years; 
there is a strong female predominance [1]. In the Optic 
Neuritis Treatment Trial (ONTT), the mean patient age 
was 31.8 years, and 77% of participants were female [2]. 
Idiopathic ON and non-arteritic anterior ischemic optic 
neuropathy (NAION) are acute optic neuropathies with 
overlapping clinical profiles. ON typically presents as pain-
ful loss of vision in younger patients and has good poten-
tial for improvement, whereas NAION typically presents 
as painless loss of vision in the middle-aged or elderly with 
usually less complete recovery. Although there has been 
some effort to differentiate ON and NAION using visual 
field testing [3], magnetic resonance imaging (MRI) [4], 
pattern electroretinography [5], or optic disc morphology 
[6], there is no gold standard for distinguishing ON from 
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NAION. 
Especially in the elderly, ON is uncommon and is often 
misdiagnosed as NAION. Although we occasionally en-
counter elderly patients with ON in the clinic, few reports 
that document ON in elderly patients have been published. 
Therefore, in this report, we described the clinical course 
and characteristics of ON in elderly patients. 
Materials and Methods
This study was a retrospective case series. We reviewed 
the medical records of patients who attended the Neuro-
ophthalmic Clinic in the Department of Ophthalmology 
at Seoul National University Hospital and were diagnosed 
with ON between January 2000 and December 2009. The 
study protocol followed the tenets of the Declaration of 
Helsinki. Informed consent was obtained, and the Institu-
tional Review Board of Seoul National University Hospital 
Clinical Research Institute approved the study. 
We searched for patients who were diagnosed with ON 
or NAION and who were also >50 years of age at the time 
of initial presentation. Patients who were finally diagnosed 
with ON by an experienced neuro-ophthalmologist (SJK) 
were included in this study. The patient age at onset, gen-
der, medical history, duration from the onset of visual 
symptoms, and presence of ocular pain on eye movement 
were noted. Determination of the best-corrected visual 
acuity (BCVA) and the presence of a relative afferent 
pupillary defect (RAPD), and visual field testing, color 
function testing, and fundoscopy were performed at the 
initial presentation and on each follow-up visit. Patients 
who underwent any treatment before the visit to our clinic 
and who had a previous visual loss history or other ocular 
abnormalities causing visual loss were excluded. Whether 
or not the patients received treatment for ON was also as-
certained. 
The diagnosis of ON was made on the basis of clinical 
symptoms, such as ocular pain or gradual visual loss over 
several days, signs of abnormal optic nerve thickening 
or enhancement on MRI with contrast, and the clinical 
course of subsequent visual recovery. To distinguish ON 
from NAION, fluorescene angiography (FAG) was also 
performed, and disc non-perfusion was ruled out. 
We examined RAPD by performing the swinging flash-
light test and identified color abnormalities by testing par-
ticipants using the Hardy-Rand-Rittler (HRR) color plate. 
Color abnormalities were graded as normal color function, 
and mild, moderate or severe defects. Visual fields were 
examined with the Goldmann perimeter (GVF) by experi-
enced technicians. The mean BCVAs were calculated after 
conversion to a logarithm of the minimal angle of resolu-
tion (logMAR). Visual acuity of the counting fingers was 
converted to 2 in logMAR, and hand movement to 3 in 
logMAR. However, light perception or no light perception 
were not actually visual measurements, so therefore these 
parameters were excluded from our calculations [7]. 
Results
Nine eyes of eight patients were included in our study. 
Patient demographics and initial examination results are 
listed in Table 1. The mean age of the patients was 60.5 
years (range, 53 to 71 years). Six patients were female, and 
two patients were male. One patient had bilateral ON. Five 
Table 1. Patient demographics and results of examination at initial presentation
Patient Gender / 
age Eye Pain on eye 
movement BCVA RAPD Disc 
swelling GVF HRR color test MRI
1 F / 71 R Y 20 / 100 Present Y Central scotoma Fail Optic nerve swelling
2 F / 67 R N HM Present N Impossible Fail Normal
3 M / 64 L Y 20 / 1000 Present Y Inferior  
  altitudinal defect
Severe RG-BY  
  defect
Optic nerve  
  enhancement
4 F / 60 L Y 20 / 100 Present N Generalized  
  decrease
Not performed Not performed
5 F / 58 L Y 20 / 200 Present N Central scotoma Severe RG-BY  
  defect
Not performed
6 F / 56 R Y CF Present Y Central scotoma Fail Optic nerve  
  enhancement
7 M / 55 R Y 20 / 70 Present Y Central scotoma Not performed Not performed
8 F / 53 R Y 20 / 100 Absent Y Superior  
  altitudinal defect
Severe RG-BY  
  defect
Optic nerve  
  enhancement
L Y NLP Present Y Impossible Fail Optic nerve  
  enhancement
BCVA = best-corrected visual acuity; RAPD = relative afferent papillary defect; GVF = Goldmann visual field; HRR = Hardy-Rand-Rit-
tler; MRI = magnetic resonance imaging; HM = hand movement; CF = counting fingers; NLP = no light perception; RG = red-green; BY = 
blue-yellow.113
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right eyes and four left eyes were involved. One patient 
had diabetes, and another patient had hyperthyroidism. 
At the time of the initial examination, eight eyes (89%) 
were accompanied by pain on eye movement. The mean 
BCVA was 20 / 400 (range, no light perception-20 / 70). 
Six eyes (66%) had disc swelling, whereas three eyes had a 
normal disc appearance. Unaffected fellow eyes had nor-
mal disc appearances with normal cup-disc ratios. In pa-
tients with unilateral ON, all affected eyes had RAPD, and 
in the patient with bilateral ON, the more severely affected 
eye had RAPD. GVF revealed four eyes with central sco-
tomas, two eyes with altitudinal defects, and one eye with 
generalized decrease of perception. Two eyes could not 
perform the field test due to poor vision. Four eyes failed 
to distinguish figures on all the plates during the HRR 
color function test, and three eyes had severe color func-
tion defects. Two eyes did not undergo the color test at the 
time of the initial examination. Five patients had MRI, and 
five eyes of four patients had abnormalities (such as optic 
nerve swelling or enhancement of the involved optic nerve) 
noted on MRI, but no participants showed abnormal brain 
enhancement (Table 1). The duration from the onset of 
decreased vision to the time of lowest visual acuity was 9.3 
days (range, 5 to 14 days). 
Among eight patients, three were treated with intrave-
nous, high-dose corticosteroid therapy and three received 
oral corticosteroid therapy. Two of the three patients who 
received oral steroids were misdiagnosed with NAION 
initially, and the other patient was treated at a primary 
ophthalmic clinic before referral to our clinic. Oral steroids 
were tapered in our clinic, and intravenous, high-dose cor-
ticosteroid therapy was not administered due to the request 
of the patient. The other two patients refused to receive in-
travenous high-dose corticosteroid therapy. Three patients 
who received intravenous steroids showed no side effects.
Two patients (cases 3 and 7) was misdiagnosed as 
NAION initially because they were elderly, had systemic 
illness such as diabetes mellitus or hypertension, and had 
disc swelling with relatively abrupt visual impairment, 
which are all more common in NAION. They also com-
plained of less specific eye pain on eye movement. One 
patient (case 3) had an altitudinal defect on GVF. However, 
no participants showed abnormal disc perfusion on FAG. 
One participant (case 3) demonstrated optic nerve en-
hancement on MRI, and both showed visual improvement 
during follow-up, which led to a final diagnosis of optic 
neuritis. 
The patients were followed for a mean of 11.3 months 
(range, 2 to 34 months), and all recovered to a BCVA of 20 
/ 40 or better within 2 months. Eight eyes gained complete 
visual recovery, and one eye achieved partial recovery. At 
the last follow-up, the mean BCVA was 20 / 20 (20 / 40 
to 20 / 16). Three eyes had remnant, small central scoto-
mas, and one eye had a small paracentral scotoma. RAPD 
remained in one eye, and mild color abnormalities were 
present in two eyes. Disc pallor was observed in five eyes 
(Table 2).
Discussion
This is the first report involving ON in patients >50 
years of age. Based on our results, ON in elderly patients 
is uncommon; there were only eight patients who visited 
our clinic between January 2000 and December 2009 
who were diagnosed with ON. The diagnosis of ON was 
based strictly on clinical judgment considering the neuro-
ophthalmic history and examination (fundoscopy, visual 
field testing, color testing, and MRI). The clinical course 
Table 2. Patient data at final examination 
Patient Eye Treatment FU (mon) BCVA RAPD Disc 
appearance GVF HRR color
test
Time to visual 
recovery ≥20 / 40
1 R Oral steroid 02 20 / 40 Absent Normal Not performed Mild RG-BY  
  defect
2 mon
2 R IV steroid 05 20 / 40 Absent Normal Small central  
  scotoma
Mild RG-BY  
  defect
1 mon
3 L Oral steroid 34 20 / 16 Absent Normal Normal Normal 1 mon
4 L No treatment 12 20 / 16 Absent Normal Normal Normal 3 wk
5 L No treatment 14 20 / 20 Absent Mild pallor Small paracentral  
  scotoma
Normal 1 mon
6 R IV steroid 04 20 / 16 Absent Mild pallor Normal Normal 1 mon
7 R Oral steroid 02 20 / 20 Present Mild pallor Small central  
  scotoma
Normal 1 mon
8 R IV steroid 17 20 / 16 Absent Pallor Normal Normal 1 wk
L IV steroid 17 20 / 20 Absent Pallor Small central  
  scotoma
Normal 1 mon
FU = follow-up period; BCVA = best-corrected visual acuity; RAPD = relative afferent papillary defect; GVF = Goldmann visual field;   
IV = intravenous; HRR = Hardy-Rand-Rittler; RG = red-green; BY = blue-yellow.114
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of visual impairment was also considered in the final diag-
nosis of ON because ON (but not NAION) is typically as-
sociated with substantial visual recovery [8]. In this study, 
all affected eyes recovered visual acuity better than 20 / 40 
within two months. This clearly demonstrates that ON had 
a good visual prognosis, even in patients >50 years of age.
Nevertheless, there is no gold standard for the diagnosis 
of ON. Rizzo and Lessell [9] reported that ON and NAION 
have many overlapping clinical profiles, and it may be dif-
ficult to differentiate between ON and NAION solely on 
nosologic grounds in some instances of acute, unilateral 
optic neuropathies. From previous reports [1,3-6], some 
distinguishing characteristics between ON and NAION are 
known, as follows: ON occurs in young patients, whereas 
NAION occurs in elderly patients; ON has a normal-color 
disc edema without hemorrhage in the acute stage and 
culminates with temporal pallor, whereas NAION has al-
titudinal or pale disc edema with hemorrhage and retinal 
arterial attenuation in the acute stage and persistent seg-
mental or altitudinal optic atrophy [6]; most ON patients 
who receive gadolinium have abnormal signal intensity 
on MRI, whereas few NAION patients show abnormali-
ties [4]; and ON has characteristic central scotoma on the 
fixation point with a sloping border, whereas NAION has 
an inferior altitudinal defect with a sharp border along the 
horizontal meridian [3]. Despite all of these differences, 
the diagnosis of ON in some instances is still a matter of 
debate. In our study, the two patients who received oral 
steroids were initially misdiagnosed with NAION and pre-
scribed oral steroids. After obtaining a detailed history and 
undergoing GVF, MRI and follow-up examinations, they 
were re-diagnosed with ON.
The diagnosis of ON in our cases was made according 
to the initial presenting features, including pain on eye 
movement, gradual visual impairment over several days, 
optic nerve abnormalities on MRI during the acute stage, 
the pattern of visual field defect on initial examination 
and follow-up, and visual recovery. Eight of nine eyes 
experienced pain on eye movement preceding visual im-
pairment in our study, whereas 92% of patients enrolled 
in the ONTT reported pain [2]. With respect to disc swell-
ing, greater than one-half of the eyes had disc swelling, 
and one-third of ONTT patients had disc swelling [2]. The 
discrepancy in the percentages of pain and disc swelling 
between our study and the ONTT may be attributed to the 
small number of cases or the different age distribution; 
further evaluation is necessary.
MRI was performed in only five patients, including one 
patient with bilateral ON; abnormal findings, such as swell-
ing or enhancement of the optic nerve, were demonstrated 
on MRI in five eyes of four patients. No patient had ab-
normal brain lesions on MRI. Considering the relationship 
between ON and multiple sclerosis, the small number of 
cases in our study made it difficult to evaluate the preva-
lence of multiple sclerosis in elderly patients. However, the 
high incidence of optic nerve abnormalities on MRI in this 
study suggested that MRI was important in the diagnosis 
of ON, which is in agreement with the findings of Rizzo et 
al. [4].
Central scotoma is the characteristic feature of the visual 
field in ON [3]. In this study, four eyes had central scotoma 
at the time of the initial examination, and two eyes showed 
central scotoma during follow-up. The latter two eyes had 
very poor visual detection of hand movements and failed 
to perform GVF initially. Two eyes that showed initial 
altitudinal defects, which is more common in NAION [3] 
but also can be seen in ON [1-3,10], recovered completely at 
the time of final examination, whereas visual field defects 
in NAION rarely recover. Therefore, follow-up visual field 
tests may aid in the diagnosis of ON.
Elderly patients are prone to decline intravenous, high-
dose corticosteroid therapy when offered due to the known 
side effects, such as sleep disturbances, mood changes, 
gastric disturbances, facial flushing, weight gain during 
the treatment period, and infections [11]. Subsequently, the 
overall treatment rate appears to be lower than that occur-
ring in pediatric or young adult patients. There is also a 
substantial tendency for multiple sclerosis to develop in pa-
tients with ON [12,13], and the intravenous administration 
of high-dose corticosteroids may lessen the risk of progres-
sion to multiple sclerosis within two years of an acute at-
tack of ON [14]. The low rate of intravenous high-dose cor-
ticosteroid treatment and age >50 years in this study might 
have influenced the later development of multiple sclerosis. 
However, the mean follow-up period for our patients was 
only 11.3 months, and the prevalence of multiple sclerosis 
is also much lower in Asian countries compared with the 
Western population [15]. Therefore, we could not further 
evaluate this hypothesis regarding ON and multiple sclero-
sis. 
The three patients who received intravenous, high-dose 
corticosteroid therapy initially had more severely impaired 
visual acuity than counting fingers. Despite steroid thera-
py, which is known to induce early visual recovery [16], it 
took >1 month to acquire a visual acuity of 20 / 40 or bet-
ter, and remnant, tiny central scotomas existed on the final 
examination in two of these patients. Based on these find-
ings, the effect of intravenous steroid therapy in elderly 
patients must be further evaluated. 
This study had some limitations. First, this was a retro-
spective study; the number of patients was small because 
ON is uncommon in elderly patients. Second, the follow-up 
period of patients was too short to evaluate their long-term 
prognosis. The favorable visual outcome of ON prohibits 
patients from returning to the clinic. The two patients who 
were followed for only two months did not visit our clinic 
after their visual acuity recovered. A comparison of clini-
cal characteristics with ON in young adults or in patients 115
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with NAION may be necessary. Some patients in this 
study were diagnosed with ON because they showed sub-
stantial visual recovery during follow-up, so the conclu-
sion that elderly patients with ON have a good prognosis 
may be biased. Moreover, visual function testing (includ-
ing contrast sensitivity or Humprey visual field testing) or 
evaluation of the fellow eye may help to understand ON 
in elderly patients. However, we believe that this study is 
worthy to report because this is the first trial to investigate 
ON in patients >50 years of age, which is contrary to the 
general perception that ON occurs between the ages of 20 
and 50 years, with a peak between 30 and 35 years of age.
In summary, we have shown that ON can develop in 
elderly patients, and the clinical features of ON in elderly 
patients do not differ from the clinical features in young 
patients. Careful diagnostic approaches are essential for 
the differential diagnosis of acute optic neuropathies in 
elderly patients. Further evaluations regarding treatment 
modalities for ON and their effect in elderly patients will 
be necessary. Although the pathogenesis of ON in elderly 
patients may differ from ON in young patients, we could 
not identify any basis by which to determine the differ-
ences. 
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